Cathepsin Inhibitor

Cathepsin Inhibitors (202):

Cat. No.	Product Name	Effect	Purity

HY-D0843

N-Ethylmaleimide	Inhibitor	99.89%
N-Ethylmaleimide (NEM) derives from maleic acid, it can alkylates free sulfhydryl. N-Ethylmaleimide is an irreversible cysteine protease inhibitor. N-ethylmaleimide specific inhibits phosphate transport in mitochondria. N-Ethylmaleimide inhibits prolyl endopeptidase with an IC₅₀ value of 6.3 μM. N-Ethylmaleimide can be used to modify cysteine residues in proteins and peptides.

HY-18234A

Leupeptin hemisulfate	Inhibitor	99.39%
Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits M^pro (the main protease of SARS-CoV-2) and also has anti-inflammatory activity.

HY-B0496

PMSF	Inhibitor	99.32%
PMSF (Phenylmethylsulfonyl fluoride) is a nonspecific and irreversible serine proteases inhibitor. PMSF inhibits some thiol proteases, non-protease enzymes, and acetylcholinesterase. PMSF can be used to prepare protein extracts from tissue and cell lysates.

HY-100229

Aloxistatin	Inhibitor	99.94%
Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor. Aloxistatin (E64d) exhibits entry-blocking effect for MERS-CoV.

HY-182757

Y1693	Inhibitor	99.91%
Y1693 is an orally active RANKL inhibitor with a K_d of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases.

HY-P10118A

Cathepsin L-IN-3 TFA	Inhibitor	98.18%
Cathepsin L-IN-3 (Compound cat L inh. 7) TFA is selective a noncovalent cathepsin L inhibitor with a K_i of 4.3 nM.

HY-158763A

MPI8 TFA	Inhibitor
MPI8 (TG0205221) TFA is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 TFA exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). MPI8 TFA can be used in clinical studies of COVID-19.

HY-15282

E-64	Inhibitor	99.96%
E-64 (Proteinase inhibitor E 64) is a potent irreversible inhibitor against general cysteine proteases with IC₅₀ of 9 nM for papain.

HY-100350

CA-074 methyl ester	Inhibitor	99.34%
CA-074 methyl ester is a specific inhibitor of Cathepsin B, which has potent bioactivities such as neuroprotective, anti-cancer, and anti-inflamatory effects.

HY-100223

Calpeptin	Inhibitor	99.17%
Calpeptin is a potent, cell penetrating calpain inhibitor, with an ID₅₀ of 40 nM for Calpain I in human platelets. Calpeptin is also an inhibitor of cathepsin K.

HY-103350

CA-074	Inhibitor	99.94%
CA-074 is a potent inhibitor of cathepsin B with a K_i of 2 to 5 nM.

HY-15533

LY 3000328	Inhibitor	99.50%
LY 3000328 (Z-FL-COCHO) is a potent and selective Cathepsin S (Cat S) inhibitor with IC₅₀s of 7.7 and 1.67 nM for hCat S and mCat S, respectively.

HY-16594

Lactacystin	Inhibitor	98.24%
Lactacystin is a potent, orally active, irreversible, cell-permeable, selective 20S proteasome inhibitor (IC₅₀ = 4.8 μM). Lactacystin also inhibits the lysosomal enzyme cathepsin A. Lactacystin inhibits cell growth and induces apoptosisand cell cycle arrest, and has antiviral and antioxidative activity. Lactacystin induces neurite outgrowth and hypertension. Lactacystin has the potential for the research of cancer, Neurological Disease, hypertension and Malaria, and so on^[2]^[6].

HY-128140

Z-FY-CHO	Inhibitor
Z-FY-CHO (Z-Phe-Tyr-CHO) is a potent and specific cathepsin L (CTSL) inhibitor.

HY-10042

Odanacatib	Inhibitor	99.80%
Odanacatib (MK-0822) is a potent and selective inhibitor of cathepsin K, with an IC₅₀ of 0.2 nM for human cathepsin K.

HY-103351

Cathepsin G Inhibitor I	Inhibitor	≥99.0%
Cathepsin G Inhibitor I (Compound 7) is a potent, selective, reversible, competitive, non-peptidic Cathepsin G inhibitor (IC₅₀ = 53 nM; K_i = 63 nM). Cathepsin G Inhibitor I can be used in research related to immune disorders.

HY-119293

K777	Inhibitor	99.14%
K777 is a potent, orally active and irreversible cysteine protease inhibitor. K777 is also a potent CYP3A4 inhibitor with an IC₅₀ of 60 nM. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 inhibits SARS-CoV and EBOV pseudovirus entry with IC₅₀ values of 0.68 nM and 0.87 nM, respectively.

HY-D0843S

N-Ethylmaleimide-d₅	Inhibitor	99.90%
N-Ethylmaleimide-d₅ is the deuterium labeled N-Ethylmaleimide. N-Ethylmaleimide (NEM), a reagent that alkylates free sulfhydryl groups, is a cysteine protease inhibitor. N-ethylmaleimide specific inhibits phosphate transport in mitochondria. N-Ethylmaleimide is also a deubiquitinating enzyme inhibitor.

HY-103353

SID 26681509	Inhibitor	99.16%
SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC₅₀ of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite *Plasmodium falciparum* and inhibits *Leishmania major* with IC₅₀s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G.

HY-P4217

Z-Gly-Pro-Arg-AMC hydrochloride	Inhibitor	99.15%
Z-Gly-Pro-Arg-AMC hydrochloride a fluorescent trypsin and cathepsin K substrate. Z-Gly-Pro-Arg-AMC hydrochloride can be used to determine trypsin and cathepsin K activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.